Search
Menu
Edmund Optics - Manufacturing Services 8/24 LB

Miravant Starts Photodynamic Therapy Trial for Psoriasis

Facebook X LinkedIn Email
SANTA BARBARA, Calif., Jan. 11 -- Miravant Medical Technologies has begun treating patients in a phase II clinical trial of PhotoPoint photodynamic therapy (PDT) for plaque psoriasis, a chronic skin disease in which the immune system triggers accelerated growth of skin cells. The clinical trial is an open-label, drug and light dose-ranging study to assess the safety and efficacy of single topical PhotoPoint treatments. The study targets 54 patients with moderate plaque-type psoriasis who will be treated at various dermatology centers and followed for up to 12 weeks.
PhotoPoint PDT uses Miravant's proprietary light-activated topical drug MV9411 to locally treat psoriatic plaques, abnormal skin lesions that can cause patients discomfort or pain.
In the two-step investigational procedure, varying doses of PhotoPoint MV9411 are applied directly to psoriatic plaques, followed by a light treatment. This proprietary drug completed a phase I drug-only safety study with healthy volunteers in 2001.
Alluxa - Optical Coatings MR 8/23

Published: January 2002
News & Features

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.